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OBJECTIVE—Bariatric surgery causes durable weight loss. Gut
hormones are implicated in obesity pathogenesis, dietary failure,
and mediating gastrointestinal bypass (GIBP) surgery weight
loss. In mice, we determined the effects of diet-induced obesity
(DIO), subsequent dieting, and GIBP surgery on ghrelin, peptide
YY (PYY), and glucagon-like peptide-1 (GLP-1). To evaluate PYY’s
role in mediating weight loss post-GIBP, we undertook GIBP
surgery in PyyKO mice.
RESEARCH DESIGN AND METHODS—Male C57BL/6 mice
randomized to a high-fat diet or control diet were killed at 4-week
intervals. DIO mice underwent switch to ad libitum low-fat diet
(DIO-switch) or caloric restriction (CR) for 4 weeks before being
killed. PyyKO mice and their DIO wild-type (WT) littermates
underwent GIBP or sham surgery and were culled 10 days post-
operatively. Fasting acyl-ghrelin, total PYY, active GLP-1 concen-
trations, stomach ghrelin expression, and colonic Pyy and
glucagon expression were determined. Fasting and postprandial
PYY and GLP-1 concentrations were assessed 30 days postsur-
gery in GIBP and sham pair-fed (sham.PF) groups.
RESULTS—DIO progressively reduced circulating fasting acyl-
ghrelin, PYY, and GLP-1 levels. CR and DIO-switch caused weight
loss but failed to restore circulating PYY to weight-appropriate
levels. After GIBP, WT mice lost weight and exhibited increased
circulating fasting PYY and colonic Pyy and glucagon expression.
In contrast, the acute effects of GIBP on body weight were lost in
PyyKO mice. Fasting PYY and postprandial PYY and GLP-1 levels
were increased in GIBP mice compared with sham.PF mice.
CONCLUSIONS—PYY plays a key role in mediating the early
weight loss observed post-GIBP, whereas relative PYY deﬁciency
during dieting may compromise weight-loss attempts. Diabetes
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besity is a global health concern, yet non-
surgical therapies remain limited. Body weight
is controlled by complex physiologic systems
in which hormones signal body energy stores
and nutrient intake to central nervous system pathways
controlling energy homeostasis. Gut hormones play an
important role in regulating body weight (1) and may be
involved in the pathogenesis of obesity (2–4). However,
the temporal relationship between obesity development
and altered gut hormones is unknown.
Dietary modiﬁcations, such as altering macronutrient
composition or restricting caloric intake, are the ﬁrst-line
obesity treatments. However, weight-loss maintenance is
often difﬁcult (5). Dieting-induced compensatory gut hor-
mone changes may contribute to the failure of weight loss
through dietary means (6). Gastrointestinal bypass (GIBP)
surgery is an effective obesity treatment, signiﬁcantly re-
ducing morbidity and mortality (7). Although mechanisms
underlying the weight-loss effects of GIBP remain largely
unknown, alterations in gut hormones engendered by these
procedures may play a causal role (8,9). Two hormones
implicated in the pathogenesis of obesity, dietary failure,
and GIBP weight-loss beneﬁts are the orexigenic hormone
acyl-ghrelin and the anorectic hormone peptide YY (PYY)
(8,9). Ghrelin is produced predominantly by the stomach;
circulating levels increase during fasting and decrease
postprandially (6). Acylation by the enzyme ghrelin O-acyl
transferase (GOAT; mBOAT4)i se s s e n t i a lf o rg h r e l i n ’sb i -
ological activity (10,11). Diet-induced weight loss increases
circulating ghrelin, potentially compromising weight-loss
maintenance (12). The effects of GIBP on circulating ghrelin
concentrations is controversial, with some studies reporting
low levels despite marked weight loss (9,13,14).
The truncated form of PYY, PYY3–36, is an anorectic
hormone (1). PYY is produced by enteroendocrine L-cells
found mainly in the distal gastrointestinal tract. Circulating
PYY3–36 concentrations increase postprandially and re-
main elevated during the intermeal period (15). Plasma
PYY levels are reduced in obesity (3). However, unlike
leptin, obese subjects remain responsive to the anorectic
actions of exogenous PYY3–36 (2). Mouse genetic studies
also implicate PYY in regulating body weight: PyyKO
mice are hyperphagic and obese (3), whereas Pyy over-
expressing mice are protected against the development of
diet-induced and genetic obesity (16). Although the de-
velopment of obesity results in reduced circulating PYY
(3,4), the effects of subsequent diet-induced weight loss
are unclear (17–19). GIBP surgery has been reported to
increase fasting and nutrient-stimulated circulating PYY
concentrations (20,21). The gut L-cells also synthesize the
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ORIGINAL ARTICLEincretin hormone glucagon-like peptide-1 (GLP-1) (1). The
effects of obesity and weight loss through dieting on cir-
culating GLP-1 levels are unclear with variable ﬁndings
reported. In contrast, the majority of studies report that
circulating nutrient-stimulated GLP-1 levels are increased
after GIBP (8).
Rodents fed a high-fat diet (HFD), analogous in fat con-
tent and calorie density to Western diets, represent an
animal model of common human obesity (22). Thus, we in-
vestigated the temporal changes in ghrelin, PYY, and GLP-1
and the changes that occur with the development of diet-
induced obesity (DIO) in mice in response to an HFD. Next,
we evaluated the effects of weight loss induced by dietary
modiﬁcation and GIBP surgery on ghrelin, PYY, and GLP-1.
To determine PYY’s role in mediating the early weight loss
seen after GIBP, we undertook GIBP in PyyKO mice.
RESEARCH DESIGN AND METHODS
Mice. Mice were maintained on a 12-h light/dark cycle (0700–1900 h) under
constant temperature and housed in speciﬁc pathogen-free facilities. All
studies were performed in accordance to the Home Ofﬁce Animal Procedures
Act (1986) U.K. and the principles and guidelines established by the European
Convention for the Protection of Laboratory Animals. Six-week-old male
C57BL/6 mice were purchased from Charles River U.K. Ltd. (Margate, U.K.).
PyyKO mice and littermate control mice on a C57BL/6 background were
generated and genotyped as described previously (3). HFD (D12451) and
control low-fat diet (LFD) (control diet) (D12450B) were obtained from Re-
search Diets (New Brunswick, NJ). The dietary composition is presented in
Supplementary Table 1.
Study 1: investigation of the temporal changes in ghrelin, PYY, and
GLP-1 with HFD-induced obesity. Male C57BL/6 mice, aged 88 weeks, were
randomized to ad libitum HFD or control diet (n=40 per group). Body weight
was monitored weekly. Ten mice from each diet group were killed after a 16-h
overnight fast after 4, 8, 12, and 16 weeks of dietary exposure. Fasted bloods
and tissues were harvested as described next.
Study 2: investigation of the effects of dietary modiﬁcation on ghrelin,
PYY, and GLP-1 in DIO mice. Male C57BL/6 mice, aged 48 weeks, were
randomized to ad libitum HFD (n=30) or LFD (n=10). After 16 weeks, the
HFD group was randomized to one of two different dietary groups for 4 weeks:
continued ad libitum HFD (DIO) (n=10) or switched to ad libitum control diet
(n=20). After switching to the control diet for 1 week, mice were then further
randomized to either dieting/caloric restriction (CR) or to continue ad libitum
control diet (DIO-switch) (n=10). CR was carried out by a step-down regimen
(23). Mice were killed after an overnight 16-h fast, and blood and tissue were
collected.
Study 3: evaluation of the effects of GIBP surgery on ghrelin, PYY, and
GLP-1 and the role of endogenous PYY in mediating weight loss. Male
PyyKO mice (n=30) and their wild-type (WT) littermates (n=30) were
weaned at 3 weeks of age. PyyKO mice gain more weight on control diet and
HFD than their WT littermates (3). Thus, to enable weight-matching, 6-week-
old WT mice were commenced on HFD and the PyyKO mice continued on
control diet until age 14 weeks when they were switched to HFD. At 24 weeks
of age, 16 weight-matched mice from each group were transported to facilities
where the surgery was to be performed. Mice were acclimatized for 1 week
before randomization to bypass or sham surgery (n=8).
Mice were fasted overnight for 16 h preoperatively. The GIBP group un-
derwent entero-gastro anastomosis (EGA) as previously described under
isoﬂurane anesthesia (24). Brieﬂy, a midline laparotomy was performed and
the pyloric sphincter was ligatured, followed by an EGA between the mid-
jejunum and stomach fundus, excluding the duodenum and the proximal je-
junum from nutrient ﬂow (Supplementary Fig. 1). Sham-operated counterparts
were identically anesthetized, a midline incision was made, and the stomach
and intestines were exposed and manipulated. The incision was kept open for
an amount of time corresponding to that for the EGA surgery. Two mice died
postoperatively, one WT sham and one PyyKO bypass, leaving seven WT
sham-operated (WT.S), eight WT bypass (WT.BP), eight PyyKO sham-operated
(PyyKO.S), and seven PyyKO bypass (PyyKO.BP). Mice were monitored daily
for general well-being and killed 10 days postoperatively after an overnight 16-h
fast. Blood and tissue were collected. The pyloric ligation was checked and was
intact in all EGA animals.
Study 4: evaluation of the effects of weight loss induced by GIBP and
pair-feeding on fasting and postprandial GLP-1 and PYY. Male C57Bl6
mice, aged 8 weeks, were ad libitum fed an HFD for 3 months. Weight-matched
groups were then randomized to either EGA or sham.pair-fed (sham.PF)
(n=5). Postsurgery the food intake/day per mouse was monitored in the
EGA group, and the pair-fed group received the same amount of HFD food
(sham.PF). Thirty days postsurgery, mice were fasted overnight and a tail
bleed was taken. The EGA group was re-fed for 90 min, and the amount of
food consumed was calculated (0.3 6 0.1 g). A postprandial tail bleed was
taken. The sham.PF group was re-fed the same amount of food in 90 min, and
a postprandial tail bleed was taken. Fasted and fed plasma active GLP-1 and
total PYY concentrations were assayed.
Terminal procedures and tissue harvesting. Mice in studies 1–3 were killed
by terminal anesthesia. Blood was collected by cardiac puncture and pro-
cessed as previously described (15). The gastrointestinal tract was dissected;
the whole stomach and a 3-cm section of descending colon were rapidly re-
moved, cleared of peritoneum, fat, and digestive contents, snap-frozen in liq-
uid nitrogen, and stored at 280°C until analysis.
Quantitative PCR analyses of gene expression. Total RNA was extracted
using TRIzol reagent, and 2 mg of RNA was reverse transcribed to cDNA. Real-
time quantitative PCR was performed as previously described using proprietary
sequence Taqman Gene Expression assay FAM/TAMRA probes (Applied Bio-
systems, Warrington, U.K.) (3).
Hormone assays. All samples were run in duplicate. To reduce interassay
variation, all samples from studies 1 and 2 were run in one assay, as were all
samples from studies 3 and 4. Plasma leptin was measured in studies 1–3a s
a marker of adiposity (25). Plasma leptin and active GLP-1 concentrations
were measured using commercially available ELISA kits (Millipore, Watford,
U.K.). There are no speciﬁcP Y Y 3 –36 assays for rodents; thus, we measured
total PYY. Plasma acyl-ghrelin and total PYY concentrations were measured
by commercially available radioimmunoassay (Millipore, Watford, U.K.)
(Supplementary Table 2 for further assay details).
Statistical analysis. Data are presented as means 6 SEM. Comparisons
between groups were made using one-way ANOVA with Dunnett post hoc
tests or Student t test where appropriate. For all statistical analyses, P , 0.05
was considered signiﬁcant.
RESULTS
Study 1: temporal changes in ghrelin, PYY, and GLP-1
with the development of HFD-induced obesity. Ad
libitum HFD access caused greater weight gain than con-
trol diet (Fig. 1A, Table 1). HFD mice displayed the
expected fasting hyperleptinemia (Table 1). Fasting cir-
culating acyl-ghrelin levels remained stable over time in
the control-diet mice, whereas fasting circulating acyl-
ghrelin progressively decreased in HFD mice (Fig. 1B). A
negative correlation between body weight and acyl-ghrelin
was observed at all time points studied (Supplementary
Fig. 2A–D). In contrast with reports of reduced stomach
ghrelin mRNA expression in DIO mice (26–28), no differ-
ences were observed in fasted stomach ghrelin expression
between control and HFD groups (Table 1). At the 4-week
time point, there was a trend toward an inverse relation-
ship between stomach ghrelin and body weight (r = 20.43,
P = 0.06). No difference was observed in stomach Mboat4
expression between HFD and control groups (Table 1).
Correlation analysis between body weight and stomach
Mboat4 expression revealed an inverse relationship at the
4-week (r = 20.48, P = 0.03; Supplementary Fig. 2E) and
8-week time points (r = 20.49, P = 0.03; Supplementary
Fig. 2F). Similarly, after 12 weeks there was a trend to-
ward a negative correlation (r = 20.39, P = 0.09), but after
16 weeks there was no relationship (r = 0.02, P = 0.93). We
found no relationship between plasma acyl-ghrelin and
stomach Mboat4 expression or between acyl-ghrelin and
stomach ghrelin expression.
Next, we evaluated the effects of HFD on fasting circu-
lating total PYY levels. After 4 weeks, total PYY levels were
similar in both groups. However, continued HFD exposure
and the development of obesity resulted in reduced fasting
total PYY levels in the HFD group (Fig. 1C). Consistent with
previous ﬁndings in humans (2,29), a negative correlation
was observed between body weight and circulating PYY
K. CHANDARANA AND ASSOCIATES
diabetes.diabetesjournals.org DIABETES, VOL. 60, MARCH 2011 811concentrations at 8, 12, and 16 weeks (Supplementary
Fig. 3). In contrast, fasted colonic Pyy expression was
unaffected (Table 1). After 4 weeks of HFD, fasted active
GLP-1 concentrations were similar in both groups
(Fig. 1D). Active GLP-1 levels tended to be lower in the
HFD group after 8 and 12 weeks of different diets and by
16 weeks were signiﬁcantly reduced (Fig. 1D). Colonic
glucagon expression was unaltered (Table 1).
Study 2: investigation of the effects of dietary
modiﬁcation on ghrelin, PYY, and GLP-1 in DIO mice.
Dietary modiﬁcation, DIO-switch or CR, reduced body
weight, whereas weight remained stable in DIO and control
mice (Supplementary Fig. 4A). After 4 weeks of dietary in-
tervention, control and DIO-switch mice had similar body
weights and CR mice weighed signiﬁcantly less (Fig. 2A).
Fasting leptin levels reﬂected body weight: highest in the
FIG. 1. Effect of HFD on body weight, fasting plasma concentrations of leptin, acyl-ghrelin, total PYY, and active GLP-1. Cohorts of mice were
exposed to control diet or HFD for 4, 8, 12, and 16 weeks and then killed in the fasted state. Body weight gain (A), plasma acyl-ghrelin (B), plasma
total PYY (C), and plasma active GLP-1 (D) were assessed. Data are expressed as means 6 SE. n=10. *P < 0.05; **P < 0.01; ***P < 0.001 for HFD
vs. control diet.
TABLE 1
Effect of HFD on fasting body weight, plasma leptin, stomach expression of ghrelin and Mboat4, and colonic expression of Pyy and
glucagon
Weeks of diet
4 8 12 16
Control HFD Control HFD Control HFD Control HFD
Body weight (g) 24.5 6 1.6 27.9 6 0.7 28.0 6 1.2 32.7 6 1.2 28.4 6 0.4 34.3 6 1.1 29.9 6 1.0 35.5 6 1.1
P , 0.05 P , 0.01 P , 0.001
Leptin (ng/mL) 0.6 6 0.1 3.2 6 1.0 0.8 6 0.2 3.1 6 1.0 1.2 6 0.5 8.3 6 2.7 1.0 6 0.1 8.5 6 2.1
P , 0.05 P , 0.05 P , 0.01
Stomach
ghrelin (AU) 1.1 6 0.1 1.2 6 0.1 1.0 6 0.1 1.1 6 0.1 1.3 6 0.1 1.3 6 0.1 1.4 6 0.1 1.3 6 0.1
Stomach
Mboat4 (AU) 0.7 6 0.5 0.7 6 0.1 0.7 6 0.1 0.6 6 0.1 0.7 6 0.1 0.6 6 0.1 0.8 6 0.1 0.7 6 0.1
Colonic Pyy (AU) 1.1 6 0.1 1.2 6 0.1 1.1 6 0.1 1.2 6 0.1 1.2 6 0.1 1.0 6 0.1 1.0 6 0.1 1.2 6 0.1
Colonic
glucagon (AU) 1.0 6 0.1 1.2 6 0.1 1.2 6 0.1 1.2 6 0.1 1.2 6 0.1 1.0 6 0.1 1.0 6 0.1 1.2 6 0.1
Data are means 6 SE. Body weights and fasting expression of stomach ghrelin and Mboat4 and colonic Pyy and glucagon after 4, 8, 12, and 16
weeks’ exposure to control diet or HFD.
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and DIO-switch mice (Fig. 2B).
As in study 1, fasting acyl-ghrelin levels were reduced in
the DIO mice compared with control and CR mice (Fig. 2C).
DIO-switch mice had fasting acyl-ghrelin concentrations
intermediate between those observed in the control and
DIO groups. Fasting acyl-ghrelin concentrations in the
CR group were comparable to those in the control group
despite CR mice weighing 21.3 6 2.0% less than control
mice. We evaluated the relationship between body weight
and plasma acyl-ghrelin and found a negative correlation
(r = 20.46, P = 0.003; Supplementary Fig. 4B). No effect
of HFD or dietary modiﬁcation on stomach ghrelin ex-
pression was apparent (ghrelin expression: control =
1.00 6 0.08 arbitrary units [AU], DIO = 0.94 6 0.06 AU,
DIO-switch = 0.94 6 0.06 AU, and CR = 0.91 6 0.08 AU).
However, stomach Mboat4 expression was reduced in the
DIO compared with the control-diet mice (P =0 . 0 2 ,F i g .2 D).
Correlation analyses revealed no relationship among stom-
ach ghrelin, Mboat4, and circulating acyl-ghrelin (data not
shown).
DIO mice had reduced circulating total PYY and active
GLP-1 concentrations compared with control mice (Fig. 2E
and F). Fasting total PYY and active GLP-1 levels tended to
increase in DIO mice subjected to dietary modiﬁcation (DIO-
switch and CR) but did not reach signiﬁcance compared
with DIO mice (Fig. 2E and F). CR mice had fasting circu-
lating total PYY and active GLP-1 levels similar to those
observed in control mice despite weighing signiﬁcantly less.
Colonic Pyy and glucagon expression were similar in all
groups (Supplementary Table 3).
Study 3: effect of EGA surgery on ghrelin, PYY, and
GLP-1 and the role of endogenous PYY in mediat-
ing weight loss. The preoperative body weights of
the four different groups—WT.S, WT.BP, PyyKO.S, and
PyyKO.BP—were similar (body weight: WT.S = 35.9 6 1.2 g,
WT.BP = 36.0 6 1.1 g, PyyKO.S = 37.7 6 2.3 g, and PyyKO.
BP = 37.0 6 1.5 g). Ten days postoperatively, WT.BP mice
weighed less (Fig. 3A, Supplementary Fig. 5A) and had lost
more body weight than WT.S mice (weight loss: WT.S =
4.7 6 0.6 g, WT.BP = 11.4 6 1.3 g, WT.S vs. WT.BP g; P ,
0.001). However, body weight and weight loss in PyyKO.S
FIG. 2. Effect of dietary modiﬁcation on body weight, fasting concentrations of leptin, acyl-ghrelin, total PYY, active GLP-1, and stomach ex-
pression of Mboat4. DIO mice were randomized to three groups, continued HFD (DIO), switch to control diet (Switch), or calorically restricted
(CR), for 4 weeks and then killed after an overnight fast. Body weight (A), plasma leptin (B), plasma acyl-ghrelin (C), stomach Mboat4 expression
(D), plasma total PYY (E), and plasma active GLP-1 (F) were assessed. Data are expressed as means 6 SE. n=10. **P < 0.01; ***P < 0.001 vs.
DIO; †P < 0.05; ††P < 0.01; †††P < 0.001 vs. control diet.
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procedure. Ten days postoperatively mice were killed in the fasted state. Body weight (A), plasma leptin (B), plasma acyl-ghrelin (C), stomach
ghrelin expression (D), plasma total PYY (E), colonic Pyy expression (F), plasma active GLP-1 (G), and colonic glucagon expression (H) were
evaluated. Data are expressed as means 6 SE. *P < 0.05; **P < 0.01; ††P < 0.01. WT.S, n=7; WT.BP, n=8; PyyKO.S, n=8; PyyKO.BP, n=7.
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4.3 6 0.6 g, PyyKO.BP = 5.1 6 0.8 g; P = 0.43). WT.BP
mice lost signiﬁcantly more weight than PyyKO.BP mice
(P = 0.002). Circulating leptin levels were reduced in
WT.BP and PyyKO.BP mice compared with sham-operated
mice (Fig. 3B). Fasting plasma acyl-ghrelin concentrations
were elevated in WT.BP mice compared with WT.S mice
(Fig. 3C). In contrast, no difference in circulating fasting
acyl-ghrelin levels was observed between PyyKO.S and
PyyKO.BP groups (Fig. 3C). In WT mice, fasting acyl-ghrelin
concentrations correlated negatively with body weight (r =
20.58, P =0 . 0 3 ) .H o w e v e r ,i nt h eK Og r o u pn oc o r r e l a t i o n
between body weight and circulating acyl-ghrelin concen-
trations was observed. Stomach ghrelin expression was
reduced in WT.BP mice (Fig. 3D). In the PyyKO.BP group,
there was a trend for reduced stomach ghrelin expression
(P = 0.18, Fig. 3D). Stomach Mboat4 expression was similar
in all four groups (stomach Mboat4: WT.S = 1.00 6 0.13 AU,
WT.BP = 0.85 6 0.10 AU, PyyKO.S = 0.86 6 0.10 AU, and
PyyKO.BP = 0.94 6 0.09 AU). No relationship was found
between stomach expression of ghrelin or Mboat4 and
circulating acyl-ghrelin levels. Fasting circulating total PYY
concentrations were markedly elevated in the WT.BP mice
compared with WT.S mice (Fig. 3E). Similarly, colonic Pyy
expression was increased in the WT.BP group (Fig. 3F). In
the WT group, there was a negative correlation between
body weight and circulating total PYY (r = 20.74, P =0 . 0 0 2 ,
Supplementary Fig. 5B) and between body weight and co-
lonic Pyy expression (r = 20.6, P =0 . 0 2 ,S u p p l e m e n t a r y
Fig. 5C). Fasting active GLP-1 concentrations were higher in
the WT.BP group compared with the WT.S group, but this
failed to reach signiﬁcance (Fig. 3E). Similar fasting active
GLP-1 concentrations were observed in the PyyKO.S and
PyyKO.BP groups (Fig. 3E). Fasting colonic glucagon ex-
pression was increased in WT.BP compared with WT.S mice
(Fig. 3F). PyyKO.S mice had higher fasting colonic gluca-
gon expression than WT.S mice (P = 0.01), but no difference
was observed between PyyKO.S and PyyKO.BP groups.
Study 4: evaluation of the effects of EGA and pair-
feeding on fasting and postprandial GLP-1 and PYY.
Preoperatively, the weights of EGA and sham.pair-fed
groups were matched (body weight: EGA group = 34.0 6
0.8 g, sham.pair-fed = 34.0 6 1.5 g). Daily food intake of all
mice preoperatively was 3.7 6 1.2 g per mouse. Post-EGA
food intake was reduced (food intake/mouse/day = 0.8 6
0.2 g). Postsurgery, body weight decreased in both groups
(Fig. 4A and B). There was a tendency for the EGA group
to weigh less, but this did not reach signiﬁcance (body
weight: EGA = 20.6 6 0.4 g, sham.pairfed = 22.9 6 1.2 g,
P = 0.10). Both fasting and postprandial levels of PYY were
signiﬁcantly higher in the EGA group compared with the
sham.pair-fed group (Fig. 4C). Although fasting active
FIG. 4. Effect of GIBP and sham.PF on body weight and fasting and postprandial concentrations of total PYY and active GLP-1. Male weight-
matched DIO mice underwent GIBP surgery or sham procedure. The sham group was then pair-fed (sham.PF) to the GIBP group. Thirty days
postsurgery, a tail bleed was taken after an overnight fast and 90 min postprandially. A: Body weight presurgery and 30 days postsurgery. B: Body
weight curves in GIBP and sham.PF groups. C: Fasting and postprandial plasma total PYY. D: Plasma fasted and postprandial active GLP-1. Data are
expressed as means 6 SE. n=5. ***P < 0.001 vs. sham.PF. BP, bypass.
K. CHANDARANA AND ASSOCIATES
diabetes.diabetesjournals.org DIABETES, VOL. 60, MARCH 2011 815GLP-1 concentrations were similar in EGA, postprandially
active GLP-1 levels were signiﬁcantly higher in the EGA
group (Fig. 4D).
DISCUSSION
We show that short-term HFD exposure per se does not
alter circulating fasted acyl-ghrelin, total PYY, or active
GLP-1 concentrations, because levels were unaltered after
4 weeks of HFD. However, with continued HFD and the
development of obesity, circulating acyl-ghrelin, total PYY,
and active GLP-1 become progressively reduced. In agree-
ment with our previous studies (3), no effect of HFD or DIO
on expression of stomach ghrelin was observed. HFD mice
tended to have lower stomach Mboat4 expression, but this
failed to reach signiﬁcance until 20 weeks of HFD (Table 2).
In study 1, we observed an inverse relationship between
stomach Mboat4 expression and body weight at 4, 8, and 12
weeks, but this disappeared by 16 weeks of HFD. These
Mboat4 changes may reﬂect alterations in leptin sensitivity
because leptin has been shown to increase stomach Mboat4
expression in the fasted state (30).
DIO-switch mice lost weight and exhibited body weights
and leptin concentrations similar to those of the control
mice, yet their acyl-ghrelin levels remained suppressed.
These ﬁndings agree with those of Weigle et al. (31), who
found that switching obese subjects from an HFD to
ad libitum LFD resulted in a reduced caloric intake and
weight loss without a concomitant increment in circulating
ghrelin. One explanation for this is that reduced dietary
fat intake improves leptin sensitivity, which in turn pre-
vents an increase in ghrelin levels. Our study is the ﬁrst
to report the effect of dietary modiﬁcation on stomach
ghrelin and Mboat4 expression in DIO mice subjected
to dietary modiﬁcation as opposed to dietary restriction
undertaken in normal-weight animals (32). We observed
no effect of diet-induced weight loss on either stomach
ghrelin or Mboat4 expression, suggesting that altered acyl-
ghrelin levels relate to factors independent of ghrelin and
Mboat4 expression, such as acylated-ghrelin degradation,
GOAT enzymatic activity, or substrate availability (28). Fur-
ther studies are now warranted to investigate the temporal
effect of high-fat feeding and subsequent dietary modiﬁ-
cation on stomach expression of ghrelin, Mboat4, and cir-
culating concentrations of acyl-ghrelin, des-acylghrelin, and
GOAT.
Consistent with human studies (2,29), a negative corre-
lation between body weight and fasting total PYY con-
centrations was observed in study 1. However, when
previously DIO mice lost weight through dietary modiﬁ-
cation, this relationship between body weight and plasma
PYY concentrations was lost, with lower circulating PYY
levels observed than would have been predicted from body
weight alone. In obese human subjects, reduced circulating
PYY concentrations result in diminished satiety (4), whereas
PYY administration to obese subjects decreases caloric
intake (2). PYY administration to obese rats during diet-
ing reduces maladaptive food-taking behavior (33), and
chronic administration reduces adiposity (34). Moreover,
in humans, PYY administration modulates neuronal ac-
tivity within homeostatic and reward brain regions; the
latter play a key role in determining feeding behavior in
our “obesogenic” environment (35). Taken together, these
ﬁndings suggest that PYY deﬁciency in obesity is likely
to reinforce obesity and that the failure of circulating PYY
concentrations to return to “weight-appropriate levels”
during dieting may hamper both weight loss and weight-
loss maintenance.
We show that colonic Pyy and glucagon expression re-
main unaltered during the development of obesity and
during subsequent weight loss through dietary means.
These ﬁndings suggest that obesity-induced modulation of
circulating total PYY and active GLP-1 levels may occur
TABLE 2
Summary of changes in circulating hormone, stomach ghrelin and Mboat4 expression, and colonic Pyy and glucagon expression
Study 1: 16 weeks of
HFD vs. control diet
Study 2: Dietary
modiﬁcation Study 3: GIBP in WT
and PyyKO mice
Study 4: EGA and
sham.PF
HFD vs.
control diet
Compared
with control
diet
Compared
with DIO
group
WT.BP
vs. WT.S
PyyKO.BP
vs. PyyKO.S
EGA vs.
sham.PF
Fasting acyl-ghrelin (pmol/L) ↓*** DIO ↓***
Switch ↓**
CR ↔
Switch ↔
CR↑***
↑* ↔ NA
Fasting total PYY (pmol/L) ↓* DIO ↓*
Switch ↔
CR ↔
Switch ↔
CR ↔
↑** NA ↑***
Fed total PYY (pmol/L) NA NA NA NA NA ↑***
Fasting active GLP-1 (pmol/L) ↓* DIO ↓*
Switch ↔
CR ↔
Switch ↔
CR ↔
↔↔ ↔
Fed active GLP-1 (pmol/L) NA NA NA NA NA ↑***
Stomach ghrelin (AU) ↔↔ ↔ ↓ ** ↔ NA
Stomach Mboat4 (AU) ↔ DIO ↓*
Switch ↔
CR ↔
Switch ↔
CR ↔
↔↔ NA
Colonic Pyy (AU) ↔↔ ↔ ↑ ** NA NA
Colonic glucagon (AU) ↔↔ ↔ ↑ * ↔ NA
Arrows indicate statistically signiﬁcant differences between groups. NA, not applicable. *P , 0.05; **P , 0.01; ***P , 0.001.
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tered breakdown.
Reports of circulating ghrelin post-GIBP in humans are
highly variable (9,12–14). These inconsistencies likely reﬂect
whether patients are studied while actively losing weight or
when weight-stable. In our studies, fasting acyl-ghrelin levels
were elevated in WT.BP mice compared with WT.S mice
and were inversely related to body weight. However,
we observed no difference in fasting acyl-ghrelin between
PyyKO.BP and PyyKO.S groups, suggesting increased
acyl-ghrelin was not due to the EGA surgical procedure
itself. Exclusion of ghrelin-producing X/A-cells from nu-
trient contact has been proposed as a potential mechanism
leading to increased circulating ghrelin levels in the early
postoperative period (36). However, in our studies the
stomach was not excluded from nutrient contact. Our
ﬁndings suggest that increased fasting acyl-ghrelin con-
centration post-GIBP is due to weight loss (36). We found
reduced stomach ghrelin expression in WT.BP mice com-
pared with WT.S and a similar trend was seen in PyyKO.
BP mice. This observation of diminished stomach ghrelin
expression in both WT and PyyKO groups suggests that
this is not due to weight loss, is independent of PYY, and
does not depend on diversion of nutrients from the stom-
ach. Reduced stomach ghrelin expression could antedate
the development of subsequent suppressed circulating acyl-
ghrelin levels that have been reported (12). Thus, further
studies are needed to examine the temporal effects of GIBP
on stomach ghrelin expression and circulating ghrelin
concentrations.
To directly evaluate PYY’s role in mediating the early
weight loss post-GIBP, we undertook EGA surgery in DIO
WT mice and PyyKO mice. We found that GIBP increased
fasting circulating PYY concentrations in WT mice and
caused a twofold increment in Pyy colonic expression.
Moreover, although WT.BP mice lost signiﬁcantly more
weight than WT.S mice, there was no difference in weight
loss between PyyKO.BP and PyyKO.S groups, suggesting
that PYY plays a key role in mediating early postoperative
weight loss.
Our studies in sham-operated mice pair-fed to the GIBP
group enabled us to investigate whether the PYY changes
post-GIBP were due to CR or weight loss. Circulating
concentrations of PYY and active GLP-1 are highest in the
postprandial state; thus, in this experiment we also eval-
uated postprandial circulating PYY and active GLP-1.
Weight loss in the EGA and sham-PF groups were similar,
but fasting and postprandial total PYY and postprandial
active GLP-1 concentrations were markedly elevated in the
EGA group. These ﬁndings suggest that EGA alters total
PYY and active GLP-1 independently of CR or weight loss.
Several different surgical procedures, sleeve gastrec-
tomy (37), jejuno-ileal bypass (38,39), Roux-en-Y gastric
bypass (RYGB) (37), and now EGA, result in increased
circulating PYY concentrations, suggesting that neither
stomach nor foregut exclusion is a prerequisite. Increased
nutrient delivery to hindgut L-cells has been suggested to
lead to increased postprandial PYY release. However, in-
creased nutrient delivery cannot explain increased fasted
PYY levels. This ﬁnding suggests that L-cell function is al-
tered directly or indirectly by GIBP. Moreover, the ﬁnding
that fasting PYY levels remain altered 20 years postsurgery
suggests that this change is long-lasting (38).
Our studies have several limitations. RYGB involves
bypassing the majority of the stomach with direct nutrient
emptying from the stomach pouch into the mid-jejunum.
Thus, nutrients are excluded from the majority of the
stomach, duodenum, and proximal jejunum. EGA surgery
undertaken in our studies (Supplementary Fig. 1) differs
from RYGB in that the stomach was not excluded but
nutrient passage into the duodenum was prevented by
pyloric ligation. The stomach was then anastomosed to the
mid-jejunum leading to bypass of the duodenum and
proximal jejunum. Thus, our ﬁndings cannot be directly
translated to RYGB surgery because the hormonal changes
may be different. To standardize feeding status, our mice
in studies 1–3 were culled in the fasted state. Circulating
acyl-ghrelin levels are highest in the fasted state and then
decrease postprandially, whereas PYY and active GLP-1
levels increase postprandially. Thus, additional insights
would be gained from undertaking nutrient-stimulated
studies. The numbers used in our studies were relatively
low, and this may have contributed to the lack of signiﬁ-
cant differences between groups in some of our studies.
Our sham EGA operation did not control for any inﬂam-
matory processes or possible postoperative ileus, which
may have resulted in greater weight loss in the bypass
mice. However, these factors would have affected WT and
PyyKO mice alike, enabling us to conclude that PYY plays
a key role in early postoperative weight reduction.
In summary, our studies provide important new in-
formation in three areas. First, our HFD temporal studies
reveal that circulating acyl-ghrelin, total PYY, and active
GLP-1 concentrations are progressively reduced with the
development of DIO. Second, dietary modiﬁcation induces
weight loss but fails to restore circulating total PYY to
weight-appropriate levels, potentially compromising on-
going dieting efforts. Third, the results from our EGA and
sham-PF groups conﬁrm that neither CR nor weight loss
per se mediate the observed increase in fasting total PYY
or increased postprandial total PYY and active GLP-1
concentration. Finally, we provide the ﬁrst direct evidence
that PYY plays a key role in mediating weight loss after
GIBP. These results suggest that an increased understanding
of the mechanisms regulating gut hormone expression and
secretion and their roles in GIBP may result in new treat-
ment strategies for obesity.
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